info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Paroxysmal Supraventricular Tachycardia (PSVT) Market: by Type (AVNRT, AVRT, PAT, WPW) Diagnosis (EPS, Echocardiogram, Holter Monitor, Event Monitor) Treatment (Physical Maneuvers, medications), End-User (Hospitals & Clinics) - Forecast Till 2030


ID: MRFR/MED/4462-HCR | 100 Pages | Author: Kinjoll Dey| July 2024

Paroxysmal Supraventricular Tachycardia (PSVT) Market Scenario


The Paroxysmal Supraventricular Tachycardia (PSVT) market is expected to register USD 490 Million at a CAGR of approximately 6.90% during the forecast period, 2023–2030.Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate that is caused by electrical impulses originating above the heart. Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heart beating. People suffering from this disorder experience sudden and unexpected occurrence of rapid heart rate that start and stop without warning. A normal heart beats between 60 to 100 beats per minute, but the heart rate of a person suffering from paroxysmal supraventricular tachycardia during an episode may exceed 150–200 beats per minute.


The prevalence of Paroxysmal Supraventricular Tachycardia (PSVT) is unknown but is projected to be around several cases per thousand persons. But, a recent study conducted by Milestone Pharmaceuticals suggested that about 1.7 million patients in the U.S. were suffering from paroxysmal supraventricular tachycardia since the last five years.


The most common types of arrhythmias include atrial fibrillation, atrial flutter, sick sinus syndrome, sinus tachycardia, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and premature ventricular contractions. Moreover, some arrhythmias may lead to more serious medical problems such as sudden stroke or cardiac arrest.


 


Intended Audience



  • Paroxysmal Supraventricular Tachycardia Drug Manufacturers and Suppliers

  • Paroxysmal Supraventricular Tachycardia Treatment Providers

  • Imaging Device Manufacturers

  • Hospitals and Clinics

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities

  • Market Research and Consulting Service Providers

  • Potential Investors


Figure 1: Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, by Region


 Paroxysmal Supraventricular Tachycardia (PSVT) Market


Segmentation


The Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, the Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented into AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT), Paroxysmal Atrial Tachycardia (PAT), and Wolff-Parkinson-White Syndrome (WPW).


On the basis of diagnosis, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into Electrophysiology Study (EPS), stress test, cardiac catheterization, coronary angiography, Electrocardiogram (ECG), echocardiogram, Holter monitor, event monitor, implantable monitor, lab tests, and others. Lab tests are further classified into blood test, urine test, and others.


On the basis of treatment, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into physical maneuvers, medications, catheter ablation, pacemaker, and cardioversion. Medication can be segmented into calcium channel blockers, beta blockers, antiarrhythmic medication, and others. Calcium channel blockers are further divided into diltiazem, verapamil, and others. The antiarrhythmic medication is divided into sotalol, amiodarone, amiodarone, flecainide, propafenone, and adenosine.


On the basis of end-user, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.


Research Methodology


 Paroxysmal Supraventricular Tachycardia (PSVT) Methodology


Sources: Annual reports, Press release, White paper, and Company presentation


Regional Analysis


The Paroxysmal Supraventricular Tachycardia (PSVT) market consists of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.


The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of stroke, raising awareness among people, and increasing healthcare expenditure. Coronary artery diseases, heart valve disorders, and heart failures are some of the common causes of heart diseases occurring in adults in North America. Thus, the increasing occurrences of heart failure support the growth of paroxysmal supraventricular tachycardia in this region.


Asia Pacific is estimated to be the most lucrative market for PSVT due to the increasing occurrence of multiple heart disorders in Asia Pacific such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.


The growing prevalence of coronary heart diseases along with the increasing medical tourism that requires surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of heart disorders are similarly supporting the growth of paroxysmal supraventricular tachycardia market.


Key Players


Some of the key players in the Paroxysmal Supraventricular Tachycardia (PSVT) market are GlaxoSmithKline PLC (U.K.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), AstraZeneca PLC (U.K.), Teva pharmaceutical industries (Israel), Sanofi SA (France), Medtronic, Inc. (U.S.), Glenmark Pharmaceuticals (U.S.), St. Jude Medical, Inc. (U.S.), BIOTRONIK SE & Co. KG (U.S.), GE Healthcare (U.S.), Boston Scientific Corporation (U.S.), Abbott Laboratories Inc. (U.S.), (Alcon) Novartis (U.S.), Siemens AG (Germany), Koninklijke Philips N.V. (U.S.), and others

Report Attribute/Metric Details
  Market Size   USD 490 Million
  CAGR 6.90%
  Base Year 2022
  Forecast Period 2023-2030
  Historical Data 2021
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline PLC (U.K.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), AstraZeneca PLC (U.K.), Teva pharmaceutical industries (Israel), Sanofi SA (France), Medtronic, Inc. (U.S.), Glenmark Pharmaceuticals (U.S.), St. Jude Medical, Inc. (U.S.), BIOTRONIK SE & Co. KG (U.S.), GE Healthcare (U.S.), Boston Scientific Corporation (U.S.), Abbott Laboratories Inc. (U.S.), (Alcon) Novartis (U.S.), Siemens AG (Germany), Koninklijke Philips N.V. (U.S.), and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers ·  Increasing demand for diagnostic outpatient surgeries ·  Increasing healthcare services ·  Availability of low cost of labor ·  Increasing number of hospitals, and better access to technology


Frequently Asked Questions (FAQ) :

Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate caused by electrical impulses originating above the heart. Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heartbeats.

Paroxysmal Supraventricular Tachycardia Market is expected to exhibit a strong 6.90% CAGR over the forecast period from 2023 to 2030.

Growing prevalence of cardiovascular diseases is the major driver for the Paroxysmal Supraventricular Tachycardia Market.

The Americas dominate the global Paroxysmal Supraventricular Tachycardia Market.

Leading players in the Paroxysmal Supraventricular Tachycardia Market include GSK, Novartis, and Pfizer, among others.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.